Email & Password

Not a member? .

Emervel ®

In 2016, the EMERVEL range, also from Galderma was integrated into their range to create one large range of hyaluronic acid fillers. This meant that EMERVEL ceased as a brand name and all products were . Please refer to the page for further information.

is a range of five cross-linked acid based dermal fillers from Q-Med, a Division of Galderma, the UK distributor of the Botulinum Toxin brand  and the dermal filler brand . It was introduced to the UK and Europe in 2011.

Emervel dermal fillers are indicated for the treatment of facial lines, for facial contouring and the correction of volume loss, as well as lip enhancement.

They are also available with the of local lidocaine for added comfort during .

hyaluronic acid.

The main component of Emervel is hyaluronic acid. This is a naturally occurring found in all living organisms. The hyaluronic acid is mixed with a called Butanediol Diglycidyl Ether (BDDE) to form a gel, which is then purified dialysis to remove trace amounts of BDDE left over from the .

The acid in is produced by a biotechnological from fermentation without using any animal .

from what the call its Balance Technology™.

Their method is designed to alter the characteristics of the acid gel via a of factors, including the levels of cross-linking (a which is needed to ensure the hyaluronic acid is long lasting), the particle sizes, which are varied to the differing within the range which aim to have a maximum effect in the different layers of the skin into which they are .

Emervel has 4 levels of cross-linking, in 4 levels of gel across the range. A lower level of will result in a softer gel for superficial and a higher level of in a firmer gel more resistant to degradation for deeper injection. Within the range, Touch, and Lips share the same smaller particle size with Deep and Volume using increasingly larger sizes for deeper skin application. size or calibration is achieved during the manufacturing process after cross-linking, by sieving the gels through different sizes of mesh.

The actual of the acid is the same throughout the range at 20mg/ml.

Some hyaluronic acid based fillers require what’s called free or non-cross-linked acid within the product in order to modify the gel (thickness) and aid in the extrusion or out of the through the syringe and needle. However, free acid is simply a liquid and has no filling properties because it is by the body quickly upon . Also by having a good affinity for water molecules, much like a sponge, the addition of it can result in swelling in the area upon . The manufacturers note that the viscoelastic properties of Emervel are produced by modifying the and sizes, as detailed above and not the concentration of acid and thus no free hyaluronic acid is which they claim makes swelling (oedema) on injection minimal.

No.

acid is completely broken down within the skin over a period of months, eventually leaving no trace of the filler.

Medical device

Trained members of the medical profession only

There are 5 different for available which include:

Emervel Touch

Touch is a soft and subtle for the treatment of wrinkles, such as lines (around the mouth) and peri-orbital lines (around the eyes, crow’s feet). It is into the superficial dermis and is available in a 1 x 1ml and comes complete with 2 x 30G ½ `Ultra Thin Wall` . It is not available with the addition of lidocaine.

Emervel Classic

provides a medium lifting effect and is ideal for moderate lines and wrinkles, such as the folds (nose-to-mouth lines). The addition of 0.3% ensures during . It is into the dermis and is available in a prefilled 1 x 1 ml syringe and comes complete with 2 x 30G ½ `Ultra Thin Wall` .

Emervel Lips

Lips is specifically formulated to enhance, define or augment the lip body and border. The addition of 0.3% ensures comfort during treatment. It is into the body of the lip and the border and is available in a 1 x 1 ml syringe and comes complete with 2 x 30G ½ `Ultra Thin Wall` .

Deep

Deep has a high volume lifting effect and integrates with the skin matrix to smooth away deep or folds such as naso-labial and lines ( lines). The addition of 0.3% ensures comfort during . It is injected into the deep dermis or upper layer and is available in a prefilled 1 x 1 ml and comes complete with 2 x 27G ½ `Ultra Thin Wall` needles.

Volume

Volume also has a very high volume lifting effect and integrates with the skin matrix to lost facial volume associated with ageing. It is suited to patients to or recontour their facial such as the cheekbones, cheeks, chin, or the whole facial oval. The addition of 0.3% ensures comfort during . It is injected into the layer and is available in a prefilled 1 x 2 ml syringe and comes complete with 2 x 23G 1 `Ultra Thin Wall` .

Treatment is not for women who are pregnant or .

dermal are contraindicated in presenting with severe allergies, particularly those with a known or to acid, as well as autoimmune disorder, porphyria and hypersensitivity to lidocaine or amide (found in lidocaine formulations).

Treatment with dermal fillers should also be in areas of skin with acute or lesions, or where other fillers, particularly permanent ones have already been .

The Technology™, employed in the of Emervel, provides a which lasts for months. In clinical trials, some have also been seen at 12 months.

Swelling, skin redness (erythema), mild pain, tenderness and itching are among the common side effects after injection with dermal fillers such as . These usually disappear within a few days after treatment.

This on the area(s) treated, the product within the range used and how much is required, as well as the practitioner doing the treatment, but price ranges are in the region of £200 – £350 per syringe, with additional syringes used in the same treatment session often at a discount.

has been tested in two multicentre, randomised, evaluator-blinded, trials. Subjects were treated with two different fillers ( vs competitor filler), one on each side of their face.

The first study compared Classic with Restylane® on 52 people in the of moderate facial lines. Classic was found to be as as Restylane at 12 and 24 weeks. It was well tolerated, the majority of people reported none or only mild site and it was associated with significantly less erythema or redness, less oedema or and less pain or tenderness than Restylane (based on diary worst scores during the first 3 weeks after baseline injection).

The second study compared Emervel® Deep with Perlane® on 68 people in the of severe facial lines. Emervel Deep was found to offer significantly better efficacy than Perlane at all visits from week 12 to week 48. The of with Deep were mild and spontaneously without treatment.

 The Emervel French survey: a prospective real-practice descriptive study of 1,822 patients for facial rejuvenation with a new hyaluronic acid filler.

Farhi D, P, P, Boineau D, H, Bodokh I, Brun P, Ascher B, Savary J; Emervel French Survey Group. Dermatology Clinic, Paris, France.
J Drugs Dermatol. 2013 May;12(5):e88-93.

rejuvenation using a range of acid fillers: efficacy, safety, and patient satisfaction over 6 months.

Rzany B, Cartier H, Kestemont P, Trevidic P, G, Kerrouche N, Dhuin JC, Ma YM.
Surg. 2012 Jul;38(7 Pt 2): .

Emervel®: full-face rejuvenation with a range of customized hyaluronic acid fillers.
Rzany B.
J Drugs Dermatol. 2012 Jan;11(1 Suppl):s4.

A complete range of hyaluronic acid filler with distinctive properties specifically for optimal tissue .

Segura S, L, Fuchez F, B. Galderma R&D, Sophia Antipolis, France.
J Drugs . 2012 Jan;11(1 Suppl):s5-8.

efficacy and high satisfaction after cheek enhancement with a new hyaluronic acid dermal filler.

Kestemont P, H, Trevidic P, Rzany B, Sattler G, Kerrouche N, Dhuin JC. CHU Pasteur, Head and Neck Surgery, Nice, France.
J Drugs . 2012 Jan;11(1 Suppl):s9-16.

rejuvenation with a range of customized hyaluronic acid fillers: and safety over six months with a specific focus on the lips.

H, P, Rzany B, Sattler G, Kestemont P, N, Dhuin JC. Centre Saint Jean, Arras, France.
J Drugs . 2012 Jan;11(1 Suppl):s17-26.

Correction of tear troughs and periorbital lines with a range of customized acid .

Rzany B, H, Kestermont P, Trevidic P, G, N, Dhuin JC. Division of Evidence Based Medicine, Charité-Universitätsmedizin, Berlin, Germany.
J Drugs . 2012 Jan;11(1 Suppl):s27-34.

and safety of a new acid dermal filler in the of nasolabial folds: 6-month results of a randomized, evaluator-blinded, intra-individual comparison study.

Rzany B, Bayerl C, Bodokh I, Boineau D, T, Queille-Roussel C, M, Sommer B, Poncet M, Guennoun M, Podda M. dEBM, Charité-Universitätsmedizin, Berlin, .
J Cosmet Laser Ther. 2011 Jun;13(3):107-12.

Efficacy and safety of a new acid dermal filler in the treatment of severe lines – 6-month results of a randomized, evaluator-blinded, intra-individual comparison study.

Ascher B, Bayerl C, Brun P, P, Rzany B, Poncet M, Guennoun M, Podda M. de Chirurgie Iéna, 11 Rue Fresnel, Paris, France.

J Cosmet . 2011 Jun;10(2):94-8.

Industry

©Copyright .com™ Ltd

All information contained within this site is carefully and maintained for accuracy of content. Please note that for purchasers of aesthetic treatments, information and provided does not an in-depth consultation with an experienced practitioner.